journal article·2024-11-26

Peroxynitrite-Free Nitric Oxide-Embedded Nanoparticles Maintain Nitric Oxide Homeostasis for Effective Revascularization of Myocardial Infarcts

Jiaxiong Zhang, Shuya Wang, Quan Sun, Jian Zhang, Xiaojing Shi, Meilian Yao, Jing Chen, Qiong Huang, Guogang Zhang, Qun Huang, Kelong Ai, Yongping Bai

ACS Nano· Volume 18· Issue 47
Publisher page

Abstract

Revascularization is crucial for treating myocardial infarction (MI). Nitric oxide (NO), at an appropriate concentration, is recognized as an ideal and potent pro-angiogenic factor. However, the application of NO in the treatment of MI is limited. Improper NO supplementation is harmful to revascularization because NO is converted into harmful peroxynitrite (ONOO – ) in MI tissues with high reactive oxygen species (ROS) levels. We overcome these obstacles by embedding biliverdin and NO into Prussian blue (PB) nanolattices to obtain an ONOO – -free NO-embedded nanomedicine (OFEN). Unlike previous NO donors, OFEN provides NO stably and spontaneously for a longer time (>7 days), which makes it possible to maintain a stable concentration of NO, suitable for angiogenesis, through dose optimization. More importantly, based on the synergy between PB and biliverdin, OFEN converts ROS into beneficial O 2 and inhibits the production of ONOO – from the source. OFEN specifically targets MI tissues and achieves sustained and stable NO delivery at the MI site. OFEN effectively promotes revascularization in the MI tissue, significantly reduces myocardial death and fibrosis, and ultimately promotes the complete recovery of cardiac function. Our strategy provides a promising approach for the treatment of myocardial and other ischemic diseases.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cardiac Ischemia and Reperfusion · Nitric Oxide and Endothelin Effects · Cardiac and Coronary Surgery Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Geriatric Medicine, Coronary Circulation Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China

National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China

Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, PR China

Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410013, PR China

Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan 410008, PR China

Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410000, PR China

Department of Child Health Care, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan 410008, PR China

Funding

Innovation-Driven Project of Central South University · Department of Science and Technology of Hunan Province · Central South University · Natural Science Foundation of Hunan Province · National Key Research and Development Program of China · Key Research and Development Program of Ningxia · Natural Science Foundation of Ningxia Province · Science and Technology Program of Hunan Province · National Natural Science Foundation of China

References (65)

Show source-provided references
1. 10.1038/s41591-022-01990-110.1038/s41591-022-01990-1 ↗
2. 10.1056/nejmc220249110.1056/nejmc2202491 ↗
3. 10.1161/01.CIR.62.5.94510.1161/01.CIR.62.5.945 ↗
4. 10.1161/CIRCULATIONAHA.115.02117710.1161/CIRCULATIONAHA.115.021177 ↗
5. 10.1053/euhj.2000.217210.1053/euhj.2000.2172 ↗
6. 10.1016/j.jacc.2023.11.00310.1016/j.jacc.2023.11.003 ↗
7. 10.1038/nm161310.1038/nm1613 ↗
8. 10.1038/s41573-021-00355-610.1038/s41573-021-00355-6 ↗
9. 10.1007/s10741-020-09953-910.1007/s10741-020-09953-9 ↗
10. 10.1126/science.abm444310.1126/science.abm4443 ↗
11. 10.1093/cvr/cvab09610.1093/cvr/cvab096 ↗
12. 10.1016/j.actbio.2019.05.00210.1016/j.actbio.2019.05.002 ↗
13. 10.1038/ni1001-90710.1038/ni1001-907 ↗
14. 10.1016/j.jacbts.2019.07.01210.1016/j.jacbts.2019.07.012 ↗
15. 10.1124/pharmrev.121.00050010.1124/pharmrev.121.000500 ↗
16. 10.1152/physrev.00029.200610.1152/physrev.00029.2006 ↗
17. 10.1152/physrev.00005.202210.1152/physrev.00005.2022 ↗
18. 10.1093/eurheartj/ehu09610.1093/eurheartj/ehu096 ↗
19. 10.1016/S0968-0896(00)82013-110.1016/S0968-0896(00)82013-1 ↗
20. 10.1038/bjc.2014.9810.1038/bjc.2014.98 ↗
21. 10.2217/nnm-2020-019110.2217/nnm-2020-0191 ↗
22. 10.1016/j.freeradbiomed.2023.07.01510.1016/j.freeradbiomed.2023.07.015 ↗
23. 10.1089/ars.2006.146410.1089/ars.2006.1464 ↗
24. 10.1021/acs.inorgchem.0c0069110.1021/acs.inorgchem.0c00691 ↗
25. 10.1021/jacs.3c0557710.1021/jacs.3c05577 ↗
26. 10.1016/j.drudis.2020.05.01410.1016/j.drudis.2020.05.014 ↗
27. 10.1093/cvr/cvab36410.1093/cvr/cvab364 ↗
28. 10.1002/advs.20220499910.1002/advs.202204999 ↗
29. 10.1016/j.trsl.2021.02.00810.1016/j.trsl.2021.02.008 ↗
30. Moghimi S. M. · Pharmacol. Rev. · 2001 · 53 · 283
31. 10.1016/j.redox.2016.01.01110.1016/j.redox.2016.01.011 ↗
32. 10.1006/jmcc.1996.999810.1006/jmcc.1996.9998 ↗
33. 10.1038/s41467-024-50854-410.1038/s41467-024-50854-4 ↗
34. 10.3390/pharmaceutics1405093010.3390/pharmaceutics14050930 ↗
35. 10.1126/scisignal.200422510.1126/scisignal.2004225 ↗
36. 10.1038/s41586-022-05060-x10.1038/s41586-022-05060-x ↗
37. 10.1002/advs.20170104310.1002/advs.201701043 ↗
38. 10.1002/advs.20210540810.1002/advs.202105408 ↗
39. 10.1038/s41467-021-24804-310.1038/s41467-021-24804-3 ↗
40. 10.1038/s44161-022-00114-910.1038/s44161-022-00114-9 ↗
41. 10.1038/s41569-022-00770-110.1038/s41569-022-00770-1 ↗
42. 10.1038/s41569-023-00913-y10.1038/s41569-023-00913-y ↗
43. 10.1161/CIRCULATIONAHA.123.06415510.1161/CIRCULATIONAHA.123.064155 ↗
44. 10.1038/lsa.2014.9010.1038/lsa.2014.90 ↗
45. 10.1016/j.trecan.2017.07.00510.1016/j.trecan.2017.07.005 ↗
46. 10.1016/j.molmed.2022.09.00410.1016/j.molmed.2022.09.004 ↗
47. 10.1016/j.cytogfr.2013.11.00210.1016/j.cytogfr.2013.11.002 ↗
48. 10.1038/nrm191110.1038/nrm1911 ↗
49. 10.1161/ATVBAHA.122.31771110.1161/ATVBAHA.122.317711 ↗
50. 10.1186/s40169-014-0028-z10.1186/s40169-014-0028-z ↗
51. 10.1111/obr.1282810.1111/obr.12828 ↗
52. 10.1016/j.molmed.2012.06.00710.1016/j.molmed.2012.06.007 ↗
53. 10.1007/s00395-023-01009-x10.1007/s00395-023-01009-x ↗
54. 10.1161/CIRCULATIONAHA.113.00122510.1161/CIRCULATIONAHA.113.001225 ↗
55. 10.1002/adma.20230823910.1002/adma.202308239 ↗
56. 10.1016/j.phrs.2020.10489710.1016/j.phrs.2020.104897 ↗
57. 10.1002/adma.20221036310.1002/adma.202210363 ↗
58. 10.1038/nrm239310.1038/nrm2393 ↗
59. 10.1002/adma.20230937010.1002/adma.202309370 ↗
60. 10.1016/j.metabol.2023.15565910.1016/j.metabol.2023.155659 ↗
61. 10.1124/mol.106.02341610.1124/mol.106.023416 ↗
62. 10.1096/fj.03-0839fje10.1096/fj.03-0839fje ↗
63. 10.1152/ajpheart.00136.200310.1152/ajpheart.00136.2003 ↗
64. 10.1038/s41591-021-01279-910.1038/s41591-021-01279-9 ↗
65. 10.1161/ATVBAHA.116.30890510.1161/ATVBAHA.116.308905 ↗